Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | AKT2 | P31751 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902626 | 0.84 | AKT1 (0.55) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL14118657 | 0.83 | AKT1 (0.54) | AKT1AKT2 | |
| SCHEMBL1902604 | 0.81 | AKT1 (0.60) | AKT1AKT2 | |
| SCHEMBL1903877 | 0.80 | MAPK14 (0.46) | AKT1MAPK14 | |
| Hydrochloric Acid SCHEMBL1898879 | 0.77 | PLA2G2A (0.55) | AKT1MAPK14 | |
| SCHEMBL1904796 | 0.77 | AKT1 (0.60) | AKT1AKT2 | |
| SCHEMBL1905819 | 0.77 | AKT1 (0.60) | AKT1AKT2 | |
| SCHEMBL1534813 | 0.77 | AKT1 (0.55) | AKT1AKT2 | |
| SCHEMBL1907297 | 0.77 | AKT1 (0.53) | AKT1AKT2 | |
| SCHEMBL12522770 | 0.77 | AKT1 (0.49) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | claimed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | claimed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | claimed |
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885MAPK14 328/4885AKT2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.